Patent US2183509A successfully refreshed from Google Patents.
US5147638A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inhibition of tumor growth by blockade of the protein C system
Assignee: Oklahoma Medical Research Foundation
•
Filing: 1989-08-04
•
Granted: 1992-09-15
•
Expires: 2009-08-04
Abstract
Abstract Compositions, and methods of use thereof, for the inhibition of tumor growth and killing of tumors having extensive microcirculation wherein the active agent is a compound blocking the Protein C system, preferably anti-Protein C antibody, anti-Protein S antibody, and C4b binding protein. In the most preferred embodiment, the Protein C blocking compound is provided in combination with a cytokine such as tumor necrosis factor (TNF), gamma interferon, interleukin-1, interleukin-2 and granulocyte-macrophage colony stimulating factor. Examples are provided demonstrating the administration of the Protein C blocking compound, alone or in combination with TNF, to dogs having canine veneral tumors, or fibrosarcoma, and an adenocarcinoma, and pigs with melanoma followed by significant tumor reduction.
Inventors
- 👤 Charles T. Esmon
- 👤 Philip C. Comp
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:31
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/40; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/191; A61K39/00; A61K39/395; A61P; A61P35/00; A61P7/00; A61P7/04; C07K1/00; C07K1/107; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4702; C07K14/4703; C07K14/745; C07K16/18; C07K16/36; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6464; C12Y; C12Y304/00; C12Y304/21; C12Y304/21069; G; G01; G01N; G01N2405/00; G01N2405/04
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
102 words
A composition for inhibition of tumor growth in a patient comprising: a pharmaceutical carrier containing a compound to block the protein C anticoagulation system selected from the group consisting of anti-protein C antibodies, anti-protein S antibodies, inactivated protein C and C4b binding protein in combination with a cytokine selected from the group consisting of tumor necrosis factor and a cytokine eliciting expression of tumor necrosis factor, wherein the combination is in an effective dosage to cause hemorrhagic necrosis of the tumor and the dosage of the cytokine in the combination is not effective in the absence of the protein C blocking compound.
Claim 2
Dependent Claim
102 words
A composition for inhibition of tumor growth in a patient comprising: a pharmaceutical carrier containing a compound to block the protein C anticoagulation system selected from the group consisting of anti-protein C antibodies, anti-protein S antibodies, inactivated protein C and C4b binding protein in combination with a cytokine selected from the group consisting of tumor necrosis factor and a cytokine eliciting expression of tumor necrosis factor, wherein the combination is in an effective dosage to cause hemorrhagic necrosis of the tumor and the dosage of the cytokine in the combination is not effective in the absence of the protein C blocking compound.
Claim 3
Dependent Claim
16 words
The composition of claim 1 wherein the Protein C blocking compound is an anti-Protein C antibody.
Claim 4
Dependent Claim
16 words
The composition of claim 1 wherein the cytokine stimulates natural killer and lymphokine-activated killer cell-mediated cytotoxicity.
Claim 5
Dependent Claim
27 words
The composition of claim 1 wherein the cytokine is selected from the group consisting of tumor necrosis factor, gamma interferon, granulocyte-macrophage colony stimulating factor, interleukin-1 and interleukin-2.
Claim 6
Dependent Claim
17 words
The composition of claim 1 further comprising a chemotherapeutic agent selectively inhibiting growth of rapidly replicating cells.
Claim 7
Dependent Claim
17 words
The composition of claim 1 further comprising endotoxin in a dosage stimulating production of tumor necrosis factor.
Claim 8
Dependent Claim
17 words
The composition of claim 1 in combination with a source of radiation causing inflammation of the tumor.
Claim 9
Dependent Claim
15 words
The composition of claim 1 in combination with a chemotherapeutic agent inhibiting replication of cells.
Claim 10
Dependent Claim
44 words
The composition of claim 4 comprising anti-Protein C antibodies in a dosage equal to or greater than the molar concentration of Protein C in the blood of the patient and tumor necrosis factor in a dosage delivering less than 100 μg TNF/kg body weight.
Claim 11
Dependent Claim
45 words
The composition of claim 4 comprising anti-Protein S antibodies in a dosage equal to or greater than the molar concentration of Protein S in the blood of the patient and tumor necrosis factor in a dosage delivering less than 100 82 g TNF/kg body weight.
Claim 12
Dependent Claim
47 words
The composition of claim 4 comprising C4b binding protein in a dosage equal to or greater than five times the molar concentration of C4b binding protein in the blood of the patient and tumor necrosis factor in a dosage delivering less than 100 μg TNF/kg body weight.
Claim 13
Independent Claim
48 words
A method for inhibition of tumor growth in a patient comprising: administering to a patient having a tumor a compound specifically blocking protein C, wherein the compound is not a cytokine, in a dosage blocking the Protein C anticoagulation system and facilitating hemorrhagic necrosis of microvasculated solid tumors.
Claim 14
Independent Claim
48 words
A method for inhibition of tumor growth in a patient comprising: administering to a patient having a tumor a compound specifically blocking protein C, wherein the compound is not a cytokine, in a dosage blocking the Protein C anticoagulation system and facilitating hemorrhagic necrosis of microvasculated solid tumors.
Claim 15
Dependent Claim
34 words
The method of claim 12 further comprising selecting the Protein C blocking compound from the group consisting of anti-Protein C antibodies, anti-Protein S antibodies, inactivated activated Protein C and C 4 b binding protein.
Claim 16
Dependent Claim
49 words
The method of claim 12 further comprising administering a cytokine selected from the group consisting of tumor necrosis factor and a cytokine eliciting expression of tumor necrosis factor, wherein the combination of protein C blocking agent and cytokine is administered in a dosage causing hemorrhagic necrosis of the tumor.
Claim 17
Dependent Claim
27 words
The method of claim 14 wherein the cytokine is selected from the group consisting of tumor necrosis factor, gamma interferon, granulocyte-macrophage colony stimulating factor, interleukin-1 and interleukin-2.
Claim 18
Dependent Claim
18 words
The method of claim 12 further comprising providing endotoxin in a dosage stimulating production of tumor necrosis factor.
Claim 19
Dependent Claim
36 words
The method of claim 13 wherein the Protein C blocking compound is anti-Protein C and the anti-Protein C is administered in a dosage equal to or greater than the level of Protein C in the blood.
Claim 20
Dependent Claim
20 words
The method of claim 17 wherein the dosage is equal to or greater than approximately 10 μg antibody/ml of blood.
Claim 21
Dependent Claim
39 words
The method of claim 13 wherein the Protein C blocking compound is C4b binding protein and the C4b binding protein is administered in a dosage equal to or greater than five times the plasma levels of C4b binding protein.
Claim 22
Dependent Claim
36 words
The method of claim 13 wherein the Protein C blocking compound is anti-Protein S and the anti-Protein S is administered in a dosage equal to or greater than the level of Protein S in the blood.
Claim 23
Dependent Claim
20 words
The method of claim 20 wherein the dosage is equal to or greater than approximately 10 μg antibody/ml of blood.
Claim 24
Dependent Claim
19 words
The method of claim 14 wherein the Protein C blocking compound and the cytokine are administered to the tumor.
Claim 25
Dependent Claim
18 words
The method of claim 14 further comprising administering a chemotherapeutic agent selectively inhibiting growth of rapidly replicating cells.
Claim 26
Dependent Claim
16 words
The method of claim 14 further comprising irradiating the patient to cause inflammation of the tumor.
Claim 27
Dependent Claim
15 words
The method of claim 14 further comprising using hyperthermia to cause inflammation of the tumor.
Claim 28
Dependent Claim
16 words
The method of claim 14 wherein the Protein C blocking compound and cytokine are administered intravenously.
Claim 29
Dependent Claim
19 words
The method of claim 14 wherein the Protein C blocking compound and cytokine are administered in a single dosage.
Claim 30
Dependent Claim
21 words
The method of claim 12 further comprising administering a compound inhibiting blocking of the Protein C system by the blocking agent.
Claim 31
Dependent Claim
29 words
The method of claim 28 wherein the inhibitory compound is selected from the group consisting of Protein C, activated Protein C, Protein S, and active site inactivated factor Xa.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-09-15 | 1996-03-16 | 1996-09-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-09-15 | 2000-03-16 | 2000-09-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-09-15 | 2004-03-16 | 2004-09-15 | $7700.00 | Window Closed / Lapsed |